Argus Forecasts Strong Price Appreciation for Merck & Co., Inc. (NYSE:MRK) Stock

Merck & Co., Inc. (NYSE:MRK) had its target price hoisted by stock analysts at Argus from $130.00 to $145.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Argus’ price target would indicate a potential upside of 10.92% from the company’s current price.

Other equities research analysts have also issued reports about the stock. Royal Bank Of Canada reiterated an “outperform” rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a research report on Wednesday, July 8th. Bank of America lifted their target price on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Morgan Stanley increased their price target on shares of Merck & Co., Inc. from $112.00 to $113.00 and gave the company an “equal weight” rating in a research report on Thursday, July 9th. Cantor Fitzgerald reiterated a “neutral” rating and set a $120.00 target price on shares of Merck & Co., Inc. in a report on Monday, July 6th. Finally, Citigroup initiated coverage on shares of Merck & Co., Inc. in a research note on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 target price for the company. Fourteen research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $135.11.

Merck & Co., Inc. Stock Performance

NYSE MRK opened at $130.72 on Tuesday. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. Merck & Co., Inc. has a 12-month low of $77.58 and a 12-month high of $135.05. The stock has a market capitalization of $322.85 billion, a price-to-earnings ratio of 104.58, a PEG ratio of 5.56 and a beta of 0.19. The business’s 50 day moving average is $124.29 and its two-hundred day moving average is $119.33.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.05% and a net margin of 4.77%.The firm had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. During the same period last year, the business posted $2.13 EPS. Merck & Co., Inc.’s quarterly revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Research analysts expect that Merck & Co., Inc. will post 2.76 EPS for the current year.

Insider Buying and Selling at Merck & Co., Inc.

In other news, EVP Chirfi Guindo sold 15,000 shares of the firm’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $131.00, for a total value of $1,965,000.00. Following the transaction, the executive vice president directly owned 46,613 shares in the company, valued at approximately $6,106,303. This trade represents a 24.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Richard R. Deluca sold 6,050 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $130.38, for a total value of $788,799.00. Following the sale, the executive vice president owned 155,487 shares in the company, valued at $20,272,395.06. The trade was a 3.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 92,603 shares of company stock worth $11,966,744 in the last ninety days. 0.17% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Kingdom Financial Group LLC. acquired a new stake in Merck & Co., Inc. in the fourth quarter worth about $25,000. Prosperity Bancshares Inc bought a new stake in shares of Merck & Co., Inc. during the 4th quarter worth about $26,000. Abound Financial LLC acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter worth approximately $26,000. Graney & King LLC lifted its stake in shares of Merck & Co., Inc. by 400.0% in the 2nd quarter. Graney & King LLC now owns 250 shares of the company’s stock worth $32,000 after acquiring an additional 200 shares during the period. Finally, IFC & Insurance Marketing Inc. acquired a new position in shares of Merck & Co., Inc. during the fourth quarter valued at approximately $31,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.